A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.

Maria Rovithi, Marlette Labots, Richard, Honeywell, Albert J. Ten Tije, Rita Ruijter, Mikkjal Skardhamar, Godefridus J. Peters, Jens Voortman, Henk M. W. Verheul

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of Clinical Oncology
Volume35
DOIs
Publication statusPublished - 20 May 2017

Cite this